Last reviewed · How we verify
NCT03351439
Efficacy of Multimodal Analgesia Following Hip Arthroscopy
NA trial testing Zopiclone in Hip Pain Chronic in 100 participants. Completed in 30 September 2021.
30 September 2021
Quick facts
| Lead sponsor | Western University, Canada |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 6 April 2018 |
| Primary completion | 30 September 2021 |
| Estimated completion | 30 September 2021 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Zopiclone (ZOPICLONE) — full drug profile →
- Gabapentin (Gabapentin) — full drug profile →
- Celebrex (celecoxib) — full drug profile →
- Percocet — full drug profile →
- Naprosyn
Conditions studied
- Hip Pain Chronic — all drugs for Hip Pain Chronic →
Sponsor
Western University, Canada
Who can join
Adults 18 to 60, any sex, with Hip Pain Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the full study is to determine whether multimodal analgesia for hip arthroscopy will reduce post-operative pain scores, narcotic consumption and hospital length-of-stay. To do this, the investigators will compare the standard of care (SOC), with routine pain management with a post-operative opioid prescription, to three different groups with multi-modal analgesia (SOC+peri-operative celecoxib, SOC+peri-operative gabapentin, and SOC+post-operative zopiclone). The investigators hypothesize that administration of multi-modal analgesia in all three treatment groups will result in improved post-operative pain control, reduced post-operative narcotic consumption and an overall reduction in post-operative length-of-stay compared to the group receiving treatment as per the standard of care. However, prior to undertaking a large multi-centre study, the investigators need to determine whether the study is feasible from data obtained with this pilot study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03351439
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Zopiclone
Trials testing the same drug.
- NCT06219902 — A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women · Phase 1 · completed
- NCT05819710 — A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects · Phase 1 · completed
- NCT04696952 — A Study to Evaluate Next Day Effects of TS-142 on Driving Performance in Healthy Subjects · Phase 1 · completed
- NCT04451187 — A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants · Phase 1 · completed
- NCT02732912 — SleepSure: A Trial to Assess the Effects of Eye Masks and Earplugs on Hospital Inpatient Sleep · Phase 3 · completed
Other recruiting trials for Hip Pain Chronic
Currently open trials in the same condition.
- NCT07327931 — PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults · NA · recruiting
- NCT06233604 — Dexamethasone vs. Dexmedetomidine for ESPB in Pain Management After Hip Arthroplasty · Phase 4 · recruiting
- NCT06221709 — Continuous Radiofrequency in Hip Osteoarthritis Pain: A Randomized Clinical Trial. · NA · recruiting
- NCT04028687 — MDR - PMCF Study for Taperloc Complete Stems · recruiting
Other Western University, Canada trials
Trials by the same sponsor.
- NCT07485062 — Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes · Phase 4 · not yet recruiting
- NCT07372755 — Feasibility and Usability of a Mobile App for Monitoring and Managing Functional Movement Disorders · not yet recruiting
- NCT07302308 — Action Outcome Latencies as a Measure of Sense of Agency in Functional Movement Disorders. · not yet recruiting
- NCT04323423 — The DURATION Study: reDUcing sedentaRy behAviour to Maintain cogniTIve functiON. · NA · withdrawn
- NCT07204301 — Enhancing Patient Comfort and Reducing Anxiety During Flexible Cystoscopy and Bladder Instillation in Bladder Cancer Pat · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03351439 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Western University, Canada
- Last refreshed: 15 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03351439.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing